Trial · NCT04377451
Metformin in Dengue With Obesity
NCT04377451, Phase 1, Phase 2, Completed, Oxford University Clinical Research Unit, Vietnam
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin in Dengue With Obesity. Trials, record NCT04377451. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04377451
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin in Dengue With Obesity
- NCT number
- NCT04377451
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 120 participants, actual
- Lead sponsor
- Oxford University Clinical Research Unit, Vietnam
- Conditions
- Dengue, Viral Infection, Metformin, Anti-inflammatory Agents, Obesity, Overweight
- Interventions
- Metformin
- First posted
- 2020-05-06
- Last updated
- 2023-08-31
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of adverse events | Up to 30 days after enrollment | Number of severe clinical symptoms and signs, including severe diarrhoea (defined as \>5 episodes watery stool/day), severe vomiting (\>=3 episodes separated by 15 minutes/24 hours), severe abdominal pain and laboratory markers of severity including -Hypoglycaemia defined as glucose \<3.9 mmol/l, Hyperlactatemia (lactate \>3 mmol/l), ALT/AST \>400 U/l |
| Secondary | Fever clearance time | Up to 7 days after enrollment | Time to temperature \<37.5 for 2 consecutive days |
| Secondary | Platelet nadir | Up to 7 days after enrollment | Lowest platelet count recorded during admission |
| Secondary | Percentage increase in hematocrit from baseline | Up to 30 days after enrollment | Percentage increase will be calculated from peak result to baseline (baseline is follow-up time-point) |
| Secondary | Percentage change in endothelial and lipid-inflammatory parameters | Up to 30 days after enrollment | Percentage change in parameters such as: VCAM1, ICAM1, leptin, adiponectin, LDL, AMPK levels will be calculated from peak result to baseline (follow-up time-point) |
| Secondary | Changes in virological parameters | Up to 7 days after enrollment | Area under the curve (AUC) of the serial measurements during days 3 - 6 (log10-transformed), time from enrollment to the first undetectable viraemia, or the first negative NS1 measurement will be compared |
| Secondary | Changes in number of immune cells | Up to 30 days after enrollment | Phenotyping CD8/4+T cell and NK cell and T cell exhaustion markers will be assessed |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04377451
GET https://conductscience.org/api/trials/v1/NCT04377451/registered